These discrepancies likely stem from distinct genetic profiles within neuroblastoma; tumors with chromosome 11q deletion or MYCN amplification tend to favor M2 phenotypes, whereas MYCN-nonamplified tumors have a higher prevalence of M1 macrophages [21, 72, 73, 85]. The gene discussed is MYCN; the disease is neuroblastoma.